2,6-Dimethylmescaline

2,6-Dimethylmescaline, or simply dimethylmescaline (DMe-M), also known as 2,6-dimethyl-3,4,5-trimethoxyphenethylamine, is a serotonin receptor modulator of the phenethylamine and scaline families related to mescaline.^[1] It is the 2,6-dimethyl derivative of mescaline.^[1]

Other namesDMe-M; Dimethylmescaline; 2,6-Dimethyl-3,4,5-trimethoxyphenethylamine; 3,4,5-Trimethoxy-2,6-dimethylphenethylamine

Drug classSerotonin receptor modulator

ATC code

• None

FormulaC₁₃H₂₁NO₃

Quick facts Clinical data, Other names ...

2,6-Dimethylmescaline

Clinical data
Other names	DMe-M; Dimethylmescaline; 2,6-Dimethyl-3,4,5-trimethoxyphenethylamine; 3,4,5-Trimethoxy-2,6-dimethylphenethylamine
Drug class	Serotonin receptor modulator
ATC code	None
Identifiers
IUPAC name 2-(3,4,5-trimethoxy-2,6-dimethylphenyl)ethan-1-amine
Chemical and physical data
Formula	C13H21NO3
Molar mass	239.315 g·mol−1
3D model (JSmol)	Interactive image
SMILES NCCc1c(C)c(OC)c(c(c1C)OC)OC
InChI InChI=1S/C13H21NO3/c1-8-10(6-7-14)9(2)12(16-4)13(17-5)11(8)15-3/h6-7,14H2,1-5H3 Key:VUZBXFVHLMPADZ-UHFFFAOYSA-N

Close

The drug shows affinity for the serotonin 5-HT_1A, 5-HT_2A, and 5-HT_2C receptors (K_i = 45 nM, 879 nM, and 1,002 nM, respectively).^[1] These affinities were 66-fold, 5.2-fold, and 7.7-fold higher than those of mescaline, respectively.^[1] The drug has not been tested in animals or humans.^[1]

2,6-Dimethylmescaline was first described in the scientific literature by Daniel Trachsel and colleagues in 2013.^[1] The source of the information cited by Trachsel and colleagues was a personal communication with David E. Nichols in 2010.^[1] It is not a controlled substance in Canada as of 2025.^[2]